Clinical Laserthermia Systems AB Stock

Equities

CLS B

SE0022049920

Advanced Medical Equipment & Technology

Delayed Nasdaq Stockholm 09:03:56 2024-07-05 am EDT 5-day change 1st Jan Change
6.012 SEK +3.98% Intraday chart for Clinical Laserthermia Systems AB +0.38% -78.22%
Sales 2024 * 35M 3.33M Sales 2025 * 54M 5.14M Capitalization 45.42M 4.33M
Net income 2024 * -43M -4.1M Net income 2025 * -27M -2.57M EV / Sales 2024 * 0.24 x
Net cash position 2024 * 37M 3.52M Net cash position 2025 * 13M 1.24M EV / Sales 2025 * 0.6 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 17
Yield 2024 *
-
Yield 2025 *
-
Free-Float 3.26%
More Fundamentals * Assessed data
Dynamic Chart
Clinical Laserthermia Systems Signs Italian Distribution Deal for Laser Ablation Therapy MT
Clinical Laserthermia Systems AB Enters into an Exclusive Distribution Agreement with Tecnogamma S.r.l CI
Clinical Laserthermia Systems AB Announces Completion of Clinical Study At Skane University Hospital CI
Clinical Laserthermia Systems AB Receives Additional Order for Clearpoint Prism Products Associated to Approximately SEK 7.5 Million CI
Clinical Laserthermia Systems to Raise SEK59 Million via Rights Issue MT
Clinical Laserthermia Systems AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Clinical Laserthermia Systems AB Enters into an Exclusive Distribution Agreement with MTEC Company CI
Clinical Laserthermia Notes US FDA Clearance for ClearPoint's Prism Bone Anchor Accessory MT
Clinical Laserthermia Systems AB Presents Initial Data from the Investigator Initiated Trial at Radboud University Medical Center Using the CLS Transberg System CI
Clinical Laserthermia Systems Receives Second Order from the National Institutes of Health Clinical Center in the US for its TRANBERG Thermal Therapy System Accessories CI
Clinical Laserthermia Systems AB Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy CI
Clinical Laserthermia Systems AB's Subsidiary CLS Americas Signs Agreement with ROSE Urology for Treatment of Prostate Cancer Patients with TRANBERG Thermal Therapy System CI
Clinical Laserthermia Systems Names Interim CFO MT
Clinical Laserthermia Systems AB Announces CFO Changes CI
Clinical Laserthermia Systems AB Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System CI
More news
1 day+7.21%
1 week+3.51%
Current month+3.51%
1 month-7.48%
3 months-60.77%
6 months-77.86%
Current year-77.54%
More quotes
1 week
5.13
Extreme 5.131
6.24
1 month
4.70
Extreme 4.7005
6.70
Current year
4.70
Extreme 4.7005
37.60
1 year
4.70
Extreme 4.7005
43.60
3 years
4.70
Extreme 4.7005
1 292.00
5 years
4.70
Extreme 4.7005
2 710.00
10 years
4.70
Extreme 4.7005
5 180.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 13-12-31
Founder 75 06-03-08
Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Director/Board Member 69 09-12-31
Chairman 74 10-12-31
Founder 75 06-03-08
More insiders
Date Price Change Volume
24-07-05 6.012 +3.98% 29 891
24-07-04 5.782 +5.18% 57,212
24-07-03 5.497 -2.48% 23,187
24-07-02 5.637 -3.48% 57,919
24-07-01 5.84 -2.49% 25,832

Delayed Quote Nasdaq Stockholm, July 05, 2024 at 06:49 am EDT

More quotes
Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise